| 臺大學術典藏 |
2022-04-25T06:44:21Z |
Prediction of Breast Cancer Recurrence Using a Deep Convolutional Neural Network Without Region-of-Interest Labeling
|
Phan N.N;Hsu C.-Y;Huang C.-C;Tseng L.-M;Chuang E.Y.; Phan N.N; Hsu C.-Y; Huang C.-C; Tseng L.-M; Chuang E.Y.; ERIC YAO-YU CHUANG |
| 臺大學術典藏 |
2022-04-25T06:44:19Z |
Predicting Breast Cancer Gene Expression Signature by Applying Deep Convolutional Neural Networks From Unannotated Pathological Images
|
Phan N.N;Huang C.-C;Tseng L.-M;Chuang E.Y.; Phan N.N; Huang C.-C; Tseng L.-M; Chuang E.Y.; ERIC YAO-YU CHUANG |
| 臺大學術典藏 |
2022-03-15T05:39:30Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; WEI-WU CHEN; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2022-03-10T06:14:59Z |
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
|
Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F. |
| 臺大學術典藏 |
2022-03-10T02:31:36Z |
Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells
|
Liu C.-Y.; Lau K.-Y.; Hsu C.-C.; Chen J.-L.; Lee C.-H.; Huang T.-T.; Chen Y.-T.; Huang C.-T.; PO-HAN LIN; Tseng L.-M. |
| 臺大學術典藏 |
2022-03-10T02:31:35Z |
Varlitinib downregulates HER/ERK signaling and induces apoptosis in triple negative breast cancer cells
|
Liu C.-Y.; Chu P.-Y.; Huang C.-T.; Chen J.-L.; Yang H.-P.; Wang W.-L.; Lau K.-Y.; Lee C.-H.; Lan T.-Y.; Huang T.-T.; PO-HAN LIN; Dai M.-S.; Tseng L.-M. |
| 臺大學術典藏 |
2022-03-10T02:31:33Z |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
PO-HAN LIN; Chen S.-C.; Tseng L.-M.; Chang K.-J.; Huang A.-C.; Cheng K.-C.; Yang K.; Wu H.-C.; Chao T.-Y.; Chang Y.-C.; Lin P.-C.; Kuo W.-H.; Kuo W.-L.; Lin C.-H.; Chen H.-M.; Yeh D.-C.; Liu L.-C.; Liu C.-Y.; Wang M.-Y.; Lo C.; Lu Y.-S.; Huang C.-S. |
| 國立成功大學 |
2022 |
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
|
Lin, P.-H.;Chen, S.-C.;Tseng, L.-M.;Chang, K.-J.;Huang, A.-C.;Cheng, K.-C.;Yang, K.;Wu, H.-C.;Chao, T.-Y.;Chang, Y.-C.;Lin, P.-C.;Kuo, W.-H.;Kuo, W.-L.;Lin, C.-H.;Chen, H.-M.;Yeh, D.-C.;Liu, Liu L.-C.;Liu, C.-Y.;Wang, M.-Y.;Lo, C.;Lu, Y.-S.;Huang, C.-S. |
| 國立成功大學 |
2022 |
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
|
Cort�s, J.;Kim, S.-B.;Chung, W.-P.;Im, S.-A.;Park, Y.H.;Hegg, R.;Kim, M.H.;Tseng, L.-M.;Petry, V.;Chung, Chung C.-F.;Iwata, H.;Hamilton, E.;Curigliano, G.;Xu, B.;Huang, C.-S.;Kim, J.H.;Chiu, J.W.Y.;Pedrini, J.L.;Lee, C.;Liu, Y.;Cathcart, J.;Bako, E.;Verma, S.;Hurvitz, S.A.;Investigators, DESTINY-Breast03 Trial |
| 臺大學術典藏 |
2021-08-31T06:29:51Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; ANN-LII CHENG; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-06-24T01:53:53Z |
Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis
|
Su J.-C.; Mar A.-C.; Wu S.-H.; Tai W.-T.; Chu P.-Y.; Wu C.-Y.; Tseng L.-M.; Lee T.-C.; Chen K.-F.; Liu C.-Y.; HAO-CHIEH CHIU; Shiau C.-W. |
| 臺大學術典藏 |
2021-06-03T06:15:36Z |
Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells
|
Liu C.-Y.; Lau K.-Y.; Hsu C.-C.; Chen J.-L.; Lee C.-H.; Huang T.-T.; Chen Y.-T.; Huang C.-T.; PO-HAN LIN; Tseng L.-M. |
| 臺大學術典藏 |
2021-06-03T06:15:35Z |
Varlitinib downregulates HER/ERK signaling and induces apoptosis in triple negative breast cancer cells
|
Liu C.-Y.;Chu P.-Y.;Huang C.-T.;Chen J.-L.;Yang H.-P.;Wang W.-L.;Lau K.-Y.;Lee C.-H.;Lan T.-Y.;Huang T.-T.;Po-Han Lin;Dai M.-S.;Tseng L.-M.; Liu C.-Y.; Chu P.-Y.; Huang C.-T.; Chen J.-L.; Yang H.-P.; Wang W.-L.; Lau K.-Y.; Lee C.-H.; Lan T.-Y.; Huang T.-T.; PO-HAN LIN; Dai M.-S.; Tseng L.-M. |
| 臺大學術典藏 |
2021-05-31T07:54:15Z |
ROCKII Ser 1366 phosphorylation reflects the activation status
|
Chuang H.-H.; Yang C.-H.; Tsay Y.-G.; Hsu C.-Y.; Tseng L.-M.; ZEE-FEN CHANG; Lee H.-H. |
| 臺大學術典藏 |
2021-05-21T07:46:14Z |
Residual risk stratification of Taiwanese breast cancers following curative therapies with the extended concurrent genes signature
|
Huang C.-S.;Tzu-Pin Lu;Liu C.-Y.;Huang C.-J.;Chiu J.-H.;Chen Y.-J.;Tseng L.-M.;Huang C.-C.; Huang C.-S.; TZU-PIN LU; Liu C.-Y.; Huang C.-J.; Chiu J.-H.; Chen Y.-J.; Tseng L.-M.; Huang C.-C. |
| 臺大學術典藏 |
2021-05-12T03:27:32Z |
Reduction of the noise in the respiration sound recording by the optimal sampling rate of sound card: A preliminary study
|
Lu B.-Y.; Lai J.-S.; HUEY-DONG WU; Chen Y.-R.; Weng Y.-L.; Tang S.-H.; Chen Y.-L.; Tseng L.-M. |
| 臺大學術典藏 |
2021-05-12T03:27:31Z |
Filtering performance of reducing the sampling rate of sound card: Perspectives on different signal-to-noise ratios
|
Lu B.-Y.; Tseng L.-M.; Hsu L.-Y.; Weng Y.-L.; Tang S.-H.; Hsueh M.-N.; HUEY-DONG WU; Lai J.-S. |
| 臺大學術典藏 |
2021-04-26T08:05:28Z |
Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study
|
CHIUN-SHENG HUANG; Yu A.L.; Tseng L.-M.; Chow L.W.C.; Hou M.-F.; Hurvitz S.A.; Schwab R.B.; L Murray J.; Chang H.-K.; Chang H.-T.; Chen S.-C.; Kim S.-B.; Hung J.-T.; Ueng S.-H.; Lee S.-H.; Chen C.-C.; Rugo H.S. |
| 臺大學術典藏 |
2021-04-26T08:05:24Z |
Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study
|
Shao Z.; Tseng L.-M.; CHIUN-SHENG HUANG; Pang D.; Yang Y.; Li W.; Liao N.; Geng C.; Zhang Q.; Xu B.; Liu D.; Kwong A.; et al (continued in the appendix) |
| 臺大學術典藏 |
2021-03-18T03:23:37Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.; WEI-WU CHEN; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; Shih T.T.-F.; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2021-03-15T06:27:34Z |
Distant metastasis in triple-negative breast cancer
|
Tseng L.M.; Hsu N.C.; Chen S.C.; Lu Y.S.; Lin C.H.; DWANG-YING CHANG; Li H.; Lin Y.C.; Chang H.K.; Chao T.C.; Ouyang F.; Hou M.F. |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer
|
YEN-SHEN LU; Lee K.S.; Chao T.-Y.; Tseng L.-M.; Chitapanarux I.; Chen S.-C.; Liu C.-T.; Sohn J.; Kim J.H.; Chang Y.-C.; Yang Y.; Shotelersuk K.; Jung K.H.; Valenti R.; Slader C.; Gao M.; Park Y.H. |
| 臺大學術典藏 |
2021-02-23T08:26:33Z |
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer
|
Lu Y.-S.; Chen D.-R.; Tseng L.-M.; Yeh D.-C.; Chen S.-T.; Hsieh C.-M.; Wang H.-C.; Yeh H.-T.; SUNG-HSIN KUO; Huang C.-S. |
| 臺大學術典藏 |
2020-08-06T07:51:48Z |
Bevacizumab preconditioning followed by etoposide and cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy
|
Lu Y.-S.;Chen T.W.-W.;Lin C.-H.;Yeh D.-C.;Tseng L.-M.;Wu P.-F.;Rau K.-M.;Chen B.-B.;Chao T.-C.;Huang S.-M.;Huang C.-S.;Tiffany Ting-Fang Shih;Cheng A.-L.;Taiwan Breast Cancer Consortium; Lu Y.-S.; Chen T.W.-W.; Lin C.-H.; Yeh D.-C.; Tseng L.-M.; Wu P.-F.; Rau K.-M.; Chen B.-B.; Chao T.-C.; Huang S.-M.; Huang C.-S.; TIFFANY TING-FANG SHIH; Cheng A.-L.; Taiwan Breast Cancer Consortium |
| 臺大學術典藏 |
2020-06-19T02:27:00Z |
Validation of Assaying Carcinoembryonic Antigen in Human Serum by Using Immunomagnetic Reduction
|
Wei P.-L.;Lee L.-T.;Tseng L.-M.;Kai-Wen Huang; Wei P.-L.; Lee L.-T.; Tseng L.-M.; KAI-WEN HUANG |
